Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks ...Middle East

Medscape - News
The JAK inhibitor shows efficacy and safety when used in combination with topical corticosteroids, and showed superiority in a head-to-head comparison with dupilumab. Medscape Medical News

Hence then, the article about upadacitinib effective and safe in atopic dermatitis at 52 weeks was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks )

Apple Storegoogle play

Last updated :

Also on site :